A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors

Investigational New Drugs

Volumn 29, Issue 1, 2011, Pages 126-130

  Nock, Charles J ^a,b   Brell, Joanna M ^a,b   Bokar, Joseph A ^a,b   Cooney, Matthew M ^a,b   Cooper, Brenda ^a,b   Gibbons, Joseph ^a,b   Krishnamurthi, Smitha ^a,b   Manda, Sudhir ^a,b   Savvides, Panayiotis ^a,b   Remick, Scot C ^a,b   Ivy, Percy ^a,b,c   Dowlati, Afshin ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Becatecarin; Oxaliplatin; Phase I; Rebeccamycin; Rebeccamycin analog; Solid tumors

Indexed keywords

BECATECARIN; OXALIPLATIN;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ESOPHAGUS TUMOR; EVIDENCE BASED MEDICINE; FATIGUE; FEMALE; GALLBLADDER TUMOR; HEART ATRIUM FIBRILLATION; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY TUMOR; LIVER CELL CARCINOMA; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE TUMOR; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUCOSIDES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 79151484294     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9322-9     Document Type: Article

References (17)

1. T Kaneko H Wong KT Okamoto, et al. 1985 Two synthetic approaches to rebeccamycin Tetrahedron Lett 26 4015 4018 1:CAS:528:DyaL28XitVOmtbc%3D 10.1016/S0040-4039(00)89281-3
2. DE Nettledone W Doyle B Krishnan, et al. 1985 Isolation and structure of rebeccamycin - a new antitumor antibiotic from Nocardia aerocolonigenes Tetrahedron Lett 26 4011 4014 10.1016/S0040-4039(00)89280-1
3. T Kaneko H Wong J Utzig, et al. 1990 Water soluble derivatives of rebeccamycin J Antibiotics 43 125 127 1:CAS:528:DyaK3cXitFOgu78%3D
4. JA Bush BH Long JJ Catino, et al. 1987 Production and biological activity of rebeccamycin, a novel antitumor agent J Antibiot 40 668 678 1:CAS:528:DyaL2sXkvFehsrw%3D 3112080
5. National Cancer Institute, Division of Cancer Treatment, Investigators Brochure Rebeccamycin Analog NSC 655649 (July1999) Bethesda, Maryland
6. C Bailly JF Riou P Colson, et al. 1997 DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin Biochem 36 3917 3929 1:CAS:528:DyaK2sXhslGhsb8%3D 10.1021/bi9624898
7. AW Tolcher SG Eckhardt J Kuhn, et al. 2001 Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory propertie J Clin Oncol 19 2937 4710 1:CAS:528:DC%2BD3MXltVGgsLw%3D 11387367
8. JF Cleary JD Berlin KD Tutsch, et al. 1997 Phase I clinical and pharmacokinetic study of rebeccamycin analog (NSC 655649) Proc Am Soc Clin Oncol 16 217a
9. A Dowlati CL Hoppel ST Ingalls, et al. 2001 Phase I clinical and pharmacokinetic trial of rebeccamycin analog given daily for 5 consecutive days J Clin Oncol 19 2309 2318 1:CAS:528:DC%2BD3MXjsFeqsro%3D 11304785
10. Dowlati A, Posey J, Ramanathan RK, et al (2009) Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers. Cancer Chemoth and Pharmacol. Apr 28. [Epub ahead of print]
11. CR Culy D Clemett LR Wiseman 2000 Oxaliplatin A review its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies Drugs 60 895 924 1:CAS:528: DC%2BD3cXosVSgs7s%3D 10.2165/00003495-200060040-00005 11085200
12. AD Ricart LA Hammond JG Kuhn, et al. 2005 Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors Clin Cancer Res 11 8728 8736 1:CAS:528:DC%2BD2MXhtlWrsbrF 10.1158/1078-0432.CCR-05-1572 16361560
13. Y Becouarn C Agostini N Trufflandier, et al. 2001 Oxaliplatin: available data in non-colorectal gastrointestinal malignancies Crit Rev Oncol Hematol 40 265 272 1:STN:280:DC%2BD3MnptFClsg%3D%3D 10.1016/S1040-8428(01)00169-X 11738949
14. H Hochster TT Chen JM Lu, et al. 2008 Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer Gynecol Oncol 108 500 504 1:CAS:528:DC%2BD1cXitlCjsbg%3D 10.1016/j.ygyno.2007.11.017 18191187
15. JC Elkas WE Winter MR Chernofsky, et al. 2007 A phase I trial of oxaliplatin and topotecan in recurrent ovarian cancer Gynecol Oncol 104 422 427 1:CAS:528:DC%2BD2sXpvVKitg%3D%3D 10.1016/j.ygyno.2006.08.011 16996118
16. M Gross-Goupil F Lokiec G Lopez, et al. 2002 Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients Eur J Cancer 38 1888 1898 1:CAS:528:DC%2BD38XmsVersrc%3D 10.1016/S0959-8049(02) 00232-0 12204671
17. LM McGregor SL Spunt VM Santana, et al. 2009 Phase I study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors Cancer 115 655 664 1:CAS:528:DC%2BD1MXislKisrY%3D 10.1002/cncr.24054 19117350